| Literature DB >> 33967623 |
Ying Xiang1,2, Lin Fu1,2, Hui-Xian Xiang1, Ling Zheng1, Zhu-Xia Tan1,2, Li-Xiang Wang1, Wei Cao1, De-Xiang Xu2, Hui Zhao1,2.
Abstract
Parkinson protein 7 (PARK7)/DJ-1 (DJ-1) is a redox sensitive molecular and stabilizer of nuclear factor erythroid 2-related factor 2 (Nrf-2). Nrf-2 regulates the downstream antioxidant defense system and exerts a significant function in patients with chronic obstructive pulmonary disease (COPD). Vitamin D receptor (VDR) is the nuclear receptor that regulates the downstream target genes. This study aimed to analyze the associations among pulmonary function, DJ-1, VDR and Nrf-2 in COPD patients. Serum was collected from 180 COPD patients and control subjects. Thirty-five lung tissues were obtained. DJ-1 was measured using ELISA and western blotting. Nrf-2 and VDR were detected by immunohistochemistry. Serum and pulmonary DJ-1 levels were lower in COPD patients than those in control subjects. Pulmonary VDR-positive nuclei were reduced in COPD patients. Nrf-2-positive nuclei were reduced in lung tissues of COPD patients. On the contrary, Nrf-2-related downstream target proteins were elevated in COPD patients. Further correlation analysis indicated that forced expiratory volume in 1 second (FEV1) was positively associated with pulmonary DJ-1, VDR and Nrf-2 in patients with COPD. In addition, there were positive correlations among DJ-1, VDR and Nrf-2 in lung tissues of COPD patients. In conclusion, DJ-1, VDR and Nrf-2 were decreased in COPD patients compared with control subjects. The reduction of DJ-1 and VDR associating with Nrf-2 downregulation may be involved in the process of COPD. © The author(s).Entities:
Keywords: COPD; DJ-1; Nrf-2; VDR; lung; pulmonary function
Year: 2021 PMID: 33967623 PMCID: PMC8100631 DOI: 10.7150/ijms.58452
Source DB: PubMed Journal: Int J Med Sci ISSN: 1449-1907 Impact factor: 3.738
Demographic and biochemical characteristics between COPD patients and control subjects
| Variables | COPD (n=180) | Control (n=180) | |
|---|---|---|---|
| Age (years) | 74.0 (68.5, 82.0) | 67.0 (50.3, 79.6) | 0.437 |
| Male, n (%) | 132 (73.2) | 114 (63.2) | 0.351 |
| Hospital stay (day) | 10.0 (7.0, 14.0) | N.S. | N.S. |
| WBC (109/L) | 6.79 (5.07, 9.52) | 5.32 (4.32, 6.93) | <0.01 |
| Neutrophils (109/L) | 4.74 (3.38, 7.22) | 3.15 (2.21, 3.96) | <0.01 |
| Lymphocyte (109/L) | 1.08 (0.78, 1.45) | 2.15 (1.72, 2.63) | <0.01 |
| Monocyte (109/L) | 0.47 (0.33, 0.68) | 0.35 (0.29, 0.44) | <0.05 |
| CRP (μg/mL) | 88.3±9.6 | 36.5±7.4 | <0.01 |
| TNF-α (ng/mL) | 103.5±7.9 | 30.3±6.2 | <0.01 |
| IL-6 (pg/mL) | 48.6±10.6 | 19.6±7.6 | <0.05 |
| MCP-1 (pg/mL) | 206.5±42.5 | 58.6±7.6 | <0.01 |
| FVC (L) | 1.88 (1.36, 2.47) | N.S. | N.S. |
| FEV1 (%) | 40.4 (27.6, 64.8) | N.S. | N.S. |
| FEV1/FVC (%) | 51.3 (43.3, 58.5) | N.S. | N.S. |
Figure 1The level of DJ-1 between COPD patients and control subjects. Serum and lung tissues were collected from COPD patients and control subjects. The level of DJ-1 was detected in serum using ELISA. (A) The level of serum DJ-1 was detected between COPD patients and control subjects. (B) The level of serum DJ-1 was evaluated in different grades of COPD patients. (C, D) The level of DJ-1 was measured in lung tissues using western blotting. (C) The protein expression of DJ-1 was evaluated in lung tissues between COPD patients and control subjects. (D) Quantitative analysis of scanning densitometry was performed. All data were represented as means ± S.E.M. (N=24). **P<0.01.
Figure 2The levels of oxidative stress markers between COPD patients and control subjects. (A, B) Pulmonary Nrf-2-positive nuclei were measured using IHC. (A) Representative field. Blue arrows indicate Nrf-2-positive nuclei. Original magnification: ×400. (B) Quantitative analysis of positive nuclei was performed. (C-F) Pulmonary HO-1 and NOX-4 were detected between COPD patients and control subjects through western blotting. (C) Representative bands of HO-1. (E) Representative bands of NOX-4. (D, F) Quantitative analysis of scanning densitometry was performed. All data were represented as means ± S.E.M. (N=24). **P<0.01.
Figure 3The level of pulmonary VDR-positive nuclei between COPD patients and control subjects. (A) Pulmonary VDR-positive nuclei were measured using IHC. Blue arrows indicate VDR-γ-positive nuclei. Original magnification: ×400. (B) Quantitative analysis of positive nuclei was performed. All data were represented as means ± S.E.M. (N=24). **P<0.01.
Figure 4Associations among FEV1, DJ-1, Nrf-2 and VDR in COPD patients. (A-C) Associations of FEV1 and pulmonary DJ-1, VDR and Nrf-2 were analyzed in COPD patients. (A) FEV1 vs DJ-1. (B) FEV1 vs Nrf-2. (C) FEV1 vs VDR. (D-F) Associations among DJ-1, VDR and Nrf-2 in lung tissues of COPD patients. (D) Nrf-2 vs DJ-1. (E) VDR vs DJ-1. (F) VDR vs Nrf-2.